Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Status:
Completed
Trial end date:
2019-09-10
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and toxicity of apatinib in patients
with platinum resistant or refractory ovarian cancer when combined with etoposide.